drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentivirally transduced autologous/allogeneic T cells expressing a CAR targeting CD20; IV infusion with dose escalation; designed for MHC-independent killing of CD20+ B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally engineered to express a CD20-specific chimeric antigen receptor. Binding to CD20 on malignant B cells triggers MHC-independent T-cell activation, proliferation, and cytotoxic killing via perforin/granzyme release and cytokine-mediated effects, leading to clearance of CD20+ cells.
drug_name
CD20-directed CAR T cells
nct_id_drug_ref
NCT06849921